In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.

Detalles Bibliográficos
Autores principales: Osanto, Susanne, Woei-A-Jin, F J Sherida H, Coenraad, Minneke J, Weijl, Nir I, Burgmans, Mark C, Burggraaf, Jacobus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732251/
https://www.ncbi.nlm.nih.gov/pubmed/36269167
http://dx.doi.org/10.1093/oncolo/oyac215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732251/
https://www.ncbi.nlm.nih.gov/pubmed/36269167
http://dx.doi.org/10.1093/oncolo/oyac215

Ejemplares similares